Patents by Inventor Hermann Oppermann
Hermann Oppermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5610021Abstract: Disclosed are novel compositions of osteogenic proteins constituting soluble forms of these proteins, and methods and compositions for distinguishing between soluble and mature forms of these proteins.Type: GrantFiled: March 4, 1994Date of Patent: March 11, 1997Assignee: Creative BioMolecules, Inc.Inventors: David C. Rueger, William K. Jones, Ronald F. Tucker, Hermann Oppermann, Engin Ozkaynak, Kuber T. Sampath
-
Patent number: 5585237Abstract: Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, contitutively expressing immortalized mammalian cell lines that exhibit high recombinant protein productivity while maintaining a low copy number per cell of the non-native recombinant DNA sequence encoding the protein of interest.Type: GrantFiled: October 25, 1993Date of Patent: December 17, 1996Assignee: Creative BioMolecules, Inc.Inventors: Hermann Oppermann, Haimanti Dorai, Paul Kaplan
-
Patent number: 5534254Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.Type: GrantFiled: October 7, 1993Date of Patent: July 9, 1996Assignees: Chiron Corporation, Creative BioMolecules, Inc.Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
-
Patent number: 5525491Abstract: Disclosed are serine-rich peptide linkers for linking two or more protein domains to form a fused protein. The peptide linkers contains at least 40% serine residues and preferably have the formula (Ser, Ser,Ser,Ser,Gly).sub.y where y is .gtoreq.1. The resulting fused domains are biologically active together or individually, have improved solubility in physiological media, and improved resistance to proteolysis.Type: GrantFiled: June 9, 1994Date of Patent: June 11, 1996Assignee: Creative BioMolecules, Inc.Inventors: James S. Huston, Hermann Oppermann, Serge N. Timasheff
-
Patent number: 5482858Abstract: Disclosed are a family of synthetic proteins having binding affinity for a preselected antigen, and multifunctional proteins having such affinity. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise V.sub.H -V.sub.L or V.sub.L -V.sub.H -like single chains wherein the V.sub.H and V.sub.L -like sequences are attached by a polypeptide linker, or individual V.sub.H or V.sub.L -like domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function, e.g., as an enzyme, toxin, binding site, or site for attachment to an immobilization media or radioactive atom.Type: GrantFiled: October 19, 1993Date of Patent: January 9, 1996Assignee: Creative BioMolecules, Inc.Inventors: James S. Huston, Hermann Oppermann
-
Patent number: 5468845Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: GrantFiled: November 1, 1993Date of Patent: November 21, 1995Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger
-
Patent number: 5354557Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: GrantFiled: December 18, 1992Date of Patent: October 11, 1994Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 5344654Abstract: A prosthetic device comprising a prosthesis coated with substantially pure osteogenic protein is disclosed. A method for biologically fixing prosthetic devices in vivo is also disclosed. In this method, a prosthesis is implanted in an individual in contact with a substantially pure osteogenic protein, enhancing the strength of the bond between the prosthesis and the existing bone at the joining site.Type: GrantFiled: June 16, 1992Date of Patent: September 6, 1994Assignee: Stryker CorporationInventors: David C. Rueger, Thangavel Kuberasampath, Hermann Oppermann, Engin Ozkaynak
-
Patent number: 5324819Abstract: Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid compositions, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.Type: GrantFiled: September 24, 1992Date of Patent: June 28, 1994Assignee: Stryker CorporationInventors: Hermann Oppermann, Thangavel Kuberasampath, David C. Rueger, Engin Ozkaynak
-
Patent number: 5266683Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: GrantFiled: February 21, 1992Date of Patent: November 30, 1993Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 5258498Abstract: Disclosed are a family of synthetic proteins having binding affinity for a preselected antigen, and multifunctional proteins having such affinity. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS) The sites comprise V.sub.H -V.sub.L or V.sub.L -V.sub.H -like single chains wherein the V.sub.H and V.sub.L -like sequences are attached by a polypeptide linker, or individual V.sub.H or V.sub.L -like domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function, e.g., as an enzyme, toxin, binding site, or site for attachment to an immobilization media or radioactive atom.Type: GrantFiled: October 1, 1992Date of Patent: November 2, 1993Assignee: Creative BioMolecules, Inc.Inventors: James S. Huston, Hermann Oppermann
-
Patent number: 5258494Abstract: Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.Type: GrantFiled: December 22, 1992Date of Patent: November 2, 1993Assignee: Stryker CorporationInventors: Hermann Oppermann, Thangavel Kuberasampath, David C. Rueger, Engin Ozkaynak
-
Patent number: 5250302Abstract: Disclosed are osteogenic devices comprising a matrix containing substantially pure mammalian osteogenic protein and methods of inducing endochondral bone growth in mammals. A partial amino acid sequence, amino acid composition, solubility properties, and various other data characterizing osteogenic protein are also disclosed, as well as a nucleic acid sequences encoding a consensus osteogenic protein.Type: GrantFiled: January 28, 1992Date of Patent: October 5, 1993Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, David C. Rueger, Thangavel Kuberasampath
-
Patent number: 5243040Abstract: Disclosed is a method and a family of materials useful for removing immune complexes from blood preferentially to soluble antibodies. The material comprises analogs of proteins which bind to the Fc region of immunoglobulin. The analogs are produced by truncating or otherwise altering the amino acid sequence of the binding protein to reduce their affinity for Fc. An array of such analogs disposed about the surface of an insoluble matrix has the ability to form multiple points of attachment to the multiple Fc's in a complex so as to bind complex strongly, whereas only weak associations are developed between the Fc region of soluble IgG and individual analogs. The preferred analogs are truncated proteins homologous to a portion of the domains of Protein A or Protein G which bind with Fc. Complex may be removed from whole blood or serum using the material and conventional plasmapheresis techniques.Type: GrantFiled: November 4, 1991Date of Patent: September 7, 1993Assignee: Creative BioMoleculesInventors: James S. Huston, Lynn Baird, Charles Cohen, Hermann Oppermann
-
Patent number: 5182365Abstract: Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.Type: GrantFiled: December 4, 1990Date of Patent: January 26, 1993Assignee: Stryker CorporationInventors: Hermann Oppermann, Thangavel Kuberasampath, David C. Rueger, Engin Ozkaynak
-
Patent number: 5132405Abstract: Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequencesThe United States government has rights in this invention pursuant to small business innovation research grant number SSS-4 1 R43 CA39870-01 and SSS-4 2 R44 CA39870-02. This application is a continuation of copending application Ser. No. 052,800 filed May 21, 1987.Type: GrantFiled: June 30, 1988Date of Patent: July 21, 1992Assignee: Creative BioMolecules, Inc.Inventors: James S. Huston, Hermann Oppermann
-
Patent number: 5091513Abstract: Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise 1) non-covalently associated or disulfide bonded synthetic V.sub.H and V.sub.L dimers, 2) V.sub.H -V.sub.L or V.sub.L -V.sub.H single chains wherein the V.sub.H and V.sub.L are attached by a polypeptide linker, or 3) individuals V.sub.H or V.sub.L domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function e.g., as an enzyme, toxin, binding site, or site of attachment to an immobilization media or radioactive atom. Methods are disclosed for producing the proteins, for designing BABS having any specificity that can be elicited by in vivo generation of antibody, and for producing analogs thereof.Type: GrantFiled: January 2, 1991Date of Patent: February 25, 1992Assignee: Creative BioMolecules, Inc.Inventors: James S. Huston, Hermann Oppermann
-
Patent number: 5084398Abstract: Disclosed is a method and a family of materials useful for removing immune complexes from blood preferentially to soluble antibodies. The material comprises analogs of proteins which bind to the Fc region of immunoglobulin. The analogs are produced by truncating or otherwise altering the amino acid sequence of the binding protein to reduce their affinity for Fc. An array of such analogs disposed about the surface of an insoluble matrix has the ability to form multiple points of attachment to the multiple Fc's in a complex so as to bind complex strongly, whereas only weak associations are developed between the Fc region of soluble IgG and inidivdual analogs. The preferred analogs are truncated proteins homologous to a portion of the domains of Protein A or Protein G which bind with Fc. Complex may be removed from whole blood or serum using the material and conventional plasmapheresis techniques.Type: GrantFiled: October 23, 1990Date of Patent: January 28, 1992Assignee: Creative BioMoleculesInventors: James S. Huston, Lynn Baird, Charles Cohen, Hermann Oppermann
-
Patent number: 5013653Abstract: Disclosed is a method for the isolation and purification of polypeptides expressed in host cells by recombinant DNA techniques. A fused polypeptide is produced containing a desired polypeptide fused to additional amino acids. The additional amino acids define a leader sequence having properties exploitable in purification, a hinge region, and a cleavage site. The hinge region is cysteine-free and has a secondary structure which serves to expose the cleavage site to a selected endopeptidase. The method of the invention involves the production of a fused polypeptide which may be efficiently isolated by exploiting the properties of the leader sequence, and then efficiently cleaved at the cleavage site in an appropriate aqueous environment by virtue of the influence of the hinge on the cleavage agent/cleavage site reaction and other properties of the fused polypeptide.Type: GrantFiled: December 28, 1989Date of Patent: May 7, 1991Assignee: Creative Biomolecules, Inc.Inventors: James S. Huston, Marc F. Charette, Charles M. Cohen, Roberto Crea, Peter C. Keck, Hermann Oppermann, David C. Rueger, Richard J. Ridge
-
Patent number: 5011691Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; (2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, (3) methods of producing osteogenic proteins using recombinant DNA technology, and (4) osteogenically and chondrogenically active synthetic protein constructs.Type: GrantFiled: February 23, 1989Date of Patent: April 30, 1991Assignee: Stryker CorporationInventors: Hermann Oppermann, Thangavel Kuberasampath, David C. Rueger, Engin Ozkaynak